These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24094530)

  • 21. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
    Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P
    Mult Scler; 2012 Dec; 18(12):1760-7. PubMed ID: 22570359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of progressive multifocal leukoencephalopathy and natalizumab.
    Aksamit AJ
    Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S; Ormeci B; Idiman E
    J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
    Calabrese M; Rocca MA; Atzori M; Mattisi I; Favaretto A; Perini P; Gallo P; Filippi M
    Ann Neurol; 2010 Mar; 67(3):376-83. PubMed ID: 20373349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive impairment in multiple sclerosis.
    Jongen PJ; Ter Horst AT; Brands AM
    Minerva Med; 2012 Apr; 103(2):73-96. PubMed ID: 22513513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Magnetic resonance imaging correlates of cognitive dysfunction in patients with multiple sclerosis].
    Filippi M
    Rev Neurol; 2000 Jun 16-30; 30(12):1253-6. PubMed ID: 10935260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.
    Moraal B; Pohl C; Uitdehaag BM; Polman CH; Edan G; Freedman MS; Hartung HP; Kappos L; Miller DH; Montalban X; Lanius V; Sandbrink R; Barkhof F
    Arch Neurol; 2009 Nov; 66(11):1345-52. PubMed ID: 19901165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Magnetic resonance imaging in multiple sclerosis.
    Napoli SQ; Bakshi R
    Rev Neurol Dis; 2005; 2(3):109-16. PubMed ID: 16400309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroimaging in multiple sclerosis.
    Miller DH; McDonald WI
    Clin Neurosci; 1994; 2(3-4):215-24. PubMed ID: 7749891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.
    Sormani MP; Stubinski B; Cornelisse P; Rocak S; Li D; De Stefano N
    Mult Scler; 2011 May; 17(5):541-9. PubMed ID: 21148262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of MRI in diagnosis and treatment of multiple sclerosis.
    Sahraian MA; Eshaghi A
    Clin Neurol Neurosurg; 2010 Sep; 112(7):609-15. PubMed ID: 20417027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.
    Rovaris M; Agosta F; Sormani MP; Inglese M; Martinelli V; Comi G; Filippi M
    Brain; 2003 Oct; 126(Pt 10):2323-32. PubMed ID: 12937086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Natalizumab (Tysabri) prescription practices of neurologists in southern France].
    Rocher F; Cohen M; Lebrun C
    Rev Neurol (Paris); 2010 Apr; 166(4):412-8. PubMed ID: 19846185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New treatment measurements for treatment effects on relapses and progression.
    Tintoré M; Sastre-Garriga J
    J Neurol Sci; 2008 Nov; 274(1-2):80-3. PubMed ID: 18822433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diffusion-tensor magnetic resonance imaging detects normal-appearing white matter damage unrelated to short-term disease activity in patients at the earliest clinical stage of multiple sclerosis.
    Gallo A; Rovaris M; Riva R; Ghezzi A; Benedetti B; Martinelli V; Falini A; Comi G; Filippi M
    Arch Neurol; 2005 May; 62(5):803-8. PubMed ID: 15883269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.
    Boster A; Hreha S; Berger JR; Bao F; Penmesta R; Tselis A; Endress C; Zak I; Perumal J; Caon C; Vazquez J; Tyler KL; Racke MK; Millis S; Khan O
    Arch Neurol; 2009 May; 66(5):593-9. PubMed ID: 19433659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Magnetization transfer can predict clinical evolution in patients with multiple sclerosis.
    Santos AC; Narayanan S; de Stefano N; Tartaglia MC; Francis SJ; Arnaoutelis R; Caramanos Z; Antel JP; Pike GB; Arnold DL
    J Neurol; 2002 Jun; 249(6):662-8. PubMed ID: 12111296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis.
    Bakshi R; Dandamudi VS; Neema M; De C; Bermel RA
    J Neuroimaging; 2005; 15(4 Suppl):30S-45S. PubMed ID: 16385017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunotherapy of multiple sclerosis: the use of magnetic resonance imaging in the evaluation of clinical trials].
    Ozawa K; Saida T
    Rinsho Shinkeigaku; 1995 Dec; 35(12):1501-3. PubMed ID: 8752444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.